🇺🇸 FDA
Patent

US 11878049

Mitapivat therapy and modulators of cytochrome P450

granted A61KA61K31/496A61K38/45

Quick answer

US patent 11878049 (Mitapivat therapy and modulators of cytochrome P450) held by Agios Pharmaceuticals, Inc. expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Agios Pharmaceuticals, Inc.
Grant date
Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/496, A61K38/45, A61K45/06